Cargando…

GIP and GLP‐1, the two incretin hormones: Similarities and differences

Gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are the two primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells. GIP and GLP‐1 exert their effects by binding to their specific recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seino, Yutaka, Fukushima, Mitsuo, Yabe, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020673/ https://www.ncbi.nlm.nih.gov/pubmed/24843404 http://dx.doi.org/10.1111/j.2040-1124.2010.00022.x

Ejemplares similares

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy
por: Moffett, R. Charlotte, et al.
Publicado: (2014)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice
por: Ahrén, Bo, et al.
Publicado: (2021)

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
por: Marrano, Nicola, et al.
Publicado: (2021)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

Investigation of endothelial nitric oxide (NO) signalling in response to the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)
por: Savage, PJ, et al.
Publicado: (2012)

GLP-1R Signaling and Functional Molecules in Incretin Therapy
por: Wan, Wenwei, et al.
Publicado: (2023)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

Macroalgal protein hydrolysates from Palmaria palmata influence the ‘incretin effect’ in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion
por: McLaughlin, C. M., et al.
Publicado: (2021)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
por: Jonik, Szymon, et al.
Publicado: (2022)

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(−/−) mice by blocking monocyte/macrophage activation
por: Kahles, Florian, et al.
Publicado: (2018)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
por: Marathe, Chinmay S., et al.
Publicado: (2011)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
por: Kuhre, Rune E., et al.
Publicado: (2014)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
por: El, K., et al.
Publicado: (2021)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE
por: LeValley, Stephanie L., et al.
Publicado: (2020)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

Incretin hormones and the satiation signal
por: Holst, J J
Publicado: (2013)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP
por: Vidal, Oscar M., et al.
Publicado: (2022)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
por: Foley, James E.
Publicado: (2019)

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
por: Ludwig, Mette Q., et al.
Publicado: (2021)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
por: Ahrén, Bo
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uucqo73ha2uv46s1c272hv8l5l